StudyGraphics #VisualAbstract: Durvalumab, trametinib, and dabrafenib triplet therapy may provide robust immunogenicity in patients with BRAF-mutated advanced melanoma January 14, 2021 | Teddy Guo Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Print Click to read the study in Nature Communications RELATED ARTICLESMORE FROM AUTHOR #VisualAbstract Using pegylated liposomal doxorubicin as maintenance therapy shows disease improvement in patients with mycosis fungoides #VisualAbstract Indatuximab ravtansine in combination with immunomodulatory drugs shows objective and clinical response in patients with relapsed or refractory multiple myeloma #VisualAbstract: Perioperative oxiplatin with S-1 significantly improves survival in patients with advanced gastric cancer or gastroesophageal adenocarcinoma undergoing D2 gastrectomy
